These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 26824321

  • 1. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.
    Ezell SA, Wang S, Bihani T, Lai Z, Grosskurth SE, Tepsuporn S, Davies BR, Huszar D, Byth KF.
    Oncotarget; 2016 Feb 23; 7(8):9163-74. PubMed ID: 26824321
    [Abstract] [Full Text] [Related]

  • 2. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, Sparano JA, Parekh S.
    Clin Cancer Res; 2012 May 01; 18(9):2534-44. PubMed ID: 22338016
    [Abstract] [Full Text] [Related]

  • 3. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ.
    Cancer Res; 2006 Jul 01; 66(13):6589-97. PubMed ID: 16818631
    [Abstract] [Full Text] [Related]

  • 4. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
    Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA.
    Oncotarget; 2015 Nov 03; 6(34):35202-17. PubMed ID: 26460954
    [Abstract] [Full Text] [Related]

  • 5. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM.
    Ann Hematol; 2013 Oct 03; 92(10):1351-8. PubMed ID: 23636313
    [Abstract] [Full Text] [Related]

  • 6. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
    Zhao MY, Auerbach A, D'Costa AM, Rapoport AP, Burger AM, Sausville EA, Stass SA, Jiang F, Sands AM, Aguilera N, Zhao XF.
    Clin Cancer Res; 2009 Mar 01; 15(5):1708-20. PubMed ID: 19223503
    [Abstract] [Full Text] [Related]

  • 7. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
    Zang C, Eucker J, Liu H, Müller A, Possinger K, Scholz CW.
    Cancer Lett; 2013 Oct 10; 339(2):288-97. PubMed ID: 23200668
    [Abstract] [Full Text] [Related]

  • 8. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H, Jang JY, Kim PJ, Kim YG, Nam SJ, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK.
    Oncotarget; 2015 Jun 20; 6(17):15035-49. PubMed ID: 25909227
    [Abstract] [Full Text] [Related]

  • 9. Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1.
    Liu Y, Fanburg BL.
    Am J Respir Cell Mol Biol; 2006 Feb 20; 34(2):182-91. PubMed ID: 16195541
    [Abstract] [Full Text] [Related]

  • 10. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
    Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A, Wasik MA.
    Cancer Res; 2005 Sep 01; 65(17):7800-8. PubMed ID: 16140948
    [Abstract] [Full Text] [Related]

  • 11. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR.
    Cancer Res; 2005 Aug 15; 65(16):7052-8. PubMed ID: 16103051
    [Abstract] [Full Text] [Related]

  • 12. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.
    Leukemia; 2005 Oct 15; 19(10):1774-82. PubMed ID: 16136169
    [Abstract] [Full Text] [Related]

  • 13. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance.
    Khamzina L, Veilleux A, Bergeron S, Marette A.
    Endocrinology; 2005 Mar 15; 146(3):1473-81. PubMed ID: 15604215
    [Abstract] [Full Text] [Related]

  • 14. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes.
    Tremblay F, Gagnon A, Veilleux A, Sorisky A, Marette A.
    Endocrinology; 2005 Mar 15; 146(3):1328-37. PubMed ID: 15576463
    [Abstract] [Full Text] [Related]

  • 15. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts.
    Cao X, Kambe F, Moeller LC, Refetoff S, Seo H.
    Mol Endocrinol; 2005 Jan 15; 19(1):102-12. PubMed ID: 15388791
    [Abstract] [Full Text] [Related]

  • 16. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
    Sathe A, Chalaud G, Oppolzer I, Wong KY, von Busch M, Schmid SC, Tong Z, Retz M, Gschwend JE, Schulz WA, Nawroth R.
    PLoS One; 2018 Jan 15; 13(1):e0190854. PubMed ID: 29357370
    [Abstract] [Full Text] [Related]

  • 17. S6K Promotes Dopaminergic Neuronal Differentiation Through PI3K/Akt/mTOR-Dependent Signaling Pathways in Human Neural Stem Cells.
    Lee JE, Lim MS, Park JH, Park CH, Koh HC.
    Mol Neurobiol; 2016 Aug 15; 53(6):3771-3782. PubMed ID: 26143260
    [Abstract] [Full Text] [Related]

  • 18. 15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of PI3K-Akt-mTOR-S6K1 signaling.
    Zhang B, Cao H, Rao GN.
    Cancer Res; 2005 Aug 15; 65(16):7283-91. PubMed ID: 16103079
    [Abstract] [Full Text] [Related]

  • 19. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L, Lv H, Li W, Song Z, Li L, Zhou S, Qiu L, Qian Z, Liu X, Feng L, Meng B, Fu K, Wang X, Pan-Hammarström Q, Wang P, Wang X, Zhang H.
    Oncotarget; 2016 May 31; 7(22):33350-62. PubMed ID: 27147575
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H, Jin X, Zhang Z, Xing Y, Kong X.
    Cell Biochem Funct; 2013 Jul 31; 31(5):427-33. PubMed ID: 23086777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.